• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Exact Sciences posts Q4 revenue gains, narrows losses

Exact Sciences posts Q4 revenue gains, narrows losses

February 16, 2010 By MassDevice staff

Exact Sciences Corp. (NSDQ:EXAS) posted fourth-quarter sales of $1.2 million for the three months ended Dec. 31, 2009, compared with negative revenues of $109,000 during the same period in 2008. Net losses narrowed 13.9 percent to $1.8 million, compared with $2.1 million during Q4 2008:

Press Release

Exact Sciences Reports Fourth-Quarter, Full-Year 2009 Financial
Results

MADISON, Wis.–(BUSINESS WIRE)–Exact
Sciences Corp.
(Nasdaq: EXAS) today announced its financial results
for the fourth quarter ended Dec. 31, 2009.

Exact reported total revenues of $1.2 million for the fourth quarter of
2009, compared to total revenues of ($109,000) during the same period of
2008. Fourth-quarter 2009 total revenues increased due to the quarterly
non-cash allocation that resulted from a 2009 intellectual property
license transaction. Total revenues for the year ended Dec. 31, 2009,
were $4.8 million, compared to total revenues of ($867,000) for the
prior year.

Exact reported a net loss of ($1.8) million, or ($0.05) a share, for the
fourth quarter of 2009. The company had a net loss of ($2.1) million, or
($0.08) a share, for the same period of 2008. Exact’s net loss for the
year ended Dec. 31, 2009, was ($9.1) million, or ($0.28) a share,
compared to ($9.7) million, or ($0.36) a share, for the prior year.

Operating expenses for the fourth quarter of 2009 were $3.0 million,
compared to $2.0 million for the same period of 2008. Operating expenses
for the year ended Dec. 31, 2009, were $13.9 million, compared to $9.1
million for the same period of 2008.

Exact ended the fourth quarter of 2009 with cash, cash equivalents and
marketable securities of $24.3 million, compared to $4.9 million at Dec.
31, 2008.

“After joining the company last April, the company’s new management
outlined three key priorities for 2009: product development, clinical
trial planning and creating a performance culture. We are pleased with
the great progress we made on each of those priorities,” said Kevin T.
Conroy, the company’s president and chief executive. “We simplified our
sDNA test and strengthened its detection capability by licensing
Hologic’s qInvader chemistry. We made significant strides in our
clinical trial planning, engaging the FDA and others in our trial
design, and initiating the recruitment of top-tier investigators. We
rebuilt our research and development team, improved our intellectual
property portfolio and strengthened our balance sheet.

“The licensing and collaboration relationship we entered with Mayo
Clinic at mid-year was an important part of the product development
progress we made during 2009,” Mr. Conroy said. “The broad research and
development collaboration with Dr. David Ahlquist and his lab is a
critical part of our ongoing product refinement efforts.”

Keywords: Exact Sciences, EXAS, fourth quarter, Q4, sales, net losses, earnings

Meta: Exact Sciences Reports Fourth-Quarter, Full-Year 2009 Financial
Results

Filed Under: Business/Financial News, Diagnostics, MassDevice Earnings Roundup, News Well, Oncology Tagged With: Exact Sciences Corp.

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy